Seegenschmiedt M H, Micke O, Muecke R
1 Center for Radiotherapy and Radiation Oncology, Strahlenzentrum Hamburg, Hamburg, Germany.
2 Department of Radiotherapy and Radiation Oncology, Franziskus Hospital Bielefeld, Bielefeld, Germany.
Br J Radiol. 2015 Jul;88(1051):20150080. doi: 10.1259/bjr.20150080. Epub 2015 May 8.
Every year in Germany about 50,000 patients are referred and treated by radiotherapy (RT) for "non-malignant disorders". This highly successful treatment is applied only for specific indications such as preservation or recovery of the quality of life by means of pain reduction or resolution and/or an improvement of formerly impaired physical body function owing to specific disease-related symptoms. Since 1995, German radiation oncologists have treated non-malignant disorders according to national consensus guidelines; these guidelines were updated and further developed over 3 years by implementation of a systematic consensus process to achieve national upgraded and accepted S2e clinical practice guidelines. Throughout this process, international standards of evaluation were implemented. This review summarizes most of the generally accepted indications for the application of RT for non-malignant diseases and presents the special treatment concepts. The following disease groups are addressed: painful degenerative skeletal disorders, hyperproliferative disorders and symptomatic functional disorders. These state of the art guidelines may serve as a platform for daily clinical work; they provide a new starting point for quality assessment, future clinical research, including the design of prospective clinical trials, and outcome research in the underrepresented and less appreciated field of RT for non-malignant disorders.
在德国,每年约有5万名患者因“非恶性疾病”接受放射治疗(RT)并得到相应治疗。这种非常成功的治疗方法仅适用于特定适应症,例如通过减轻或消除疼痛和/或改善因特定疾病相关症状而先前受损的身体功能来维持或恢复生活质量。自1995年以来,德国放射肿瘤学家一直根据国家共识指南治疗非恶性疾病;这些指南在3年时间里通过实施系统的共识流程进行了更新和进一步完善,以达成国家升级并被认可的S2e临床实践指南。在整个过程中,采用了国际评估标准。本综述总结了RT用于非恶性疾病的大多数普遍认可的适应症,并介绍了特殊的治疗理念。涉及以下疾病组:疼痛性退行性骨骼疾病、增生性疾病和症状性功能性疾病。这些最新指南可作为日常临床工作的平台;它们为质量评估、未来临床研究(包括前瞻性临床试验的设计)以及在RT治疗非恶性疾病这一代表性不足且较少受到重视的领域的结局研究提供了新的起点。